Drug developer QGC boosts European capacity to identify and select high potential molecules in the lab

Jersey City, New Jersey—October 29, 2007—Quantum Genomics Corp.(QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, announces today the acquisition of Eurobiobiz SAS, a company specializing in the identification and development of high value-added projects in the field of life sciences and academic research. Financial terms were not disclosed.

QGC’s core business is the development of new drugs. In order to do this, the company identifies research projects involving innovative compounds with a high potential of reaching the clinic. Eurobiobiz has developed a tried and  tested evaluation method for this type of research project and holds a unique position in Europe in this domain. This acquisition means that a dedicated and experienced team now joins QGC.QGC has already worked with this team for more than a year on the evaluation of a number of scientific projects.Bringing the two companies together will further improve this synergy.

“Through this acquisition, QGC boosts its business development and its ability to detect useful molecules, especially in Eastern Europe where Eurobiobiz has particularly good connections and where scientific resources are underexploited,” said Lionel Ségard, chairman and CEO of QGC.“Eurobiobiz’s experience of both in- and out-licensing as well as its know-how in training scientists Europe-wide, is a real plus for QGC and will enable us to accelerate the development of our molecules from the scientist’s bench through to late stage clinical trials.”

“I am delighted that Eurobiobiz is adding to its capabilities by joining QGC ,” said Michel Lepers, founder and director of Eurobiobiz. “By combining our know-how, we are creating a unique entity in Europe which will become the privileged partner of biomedical research in Europe, and bring to market innovative molecules developed from academic research.”

About Eurobiobiz
Eurobiobiz is specialized in the identification and management of high valueadded projects in the field of life sciences and academic research. Eurobiobiz has acquired in-depth experience in evaluating companies, technology transfer and training. The company organizes regular “Bio Entrepreneur Boot Camps” in collaboration with the European Commission to encourage the creation of innovative science based companies.

Since the company was set up in 1999, Eurobiobiz has trained more than 650
scientists across Europe and been actively involved in the creation and development phases of more than 40 biotechnology companies, including
Newron (Italy), Kibow Biotech (USA) and Aptys Pharmaceuticals (France).
For more information go to www.eurobiobiz.com

About Quantum Genomics Corp.
QGC is a biotechnology company seeking to develop new therapies in areas
where an unmet medical need exists. QGC focus is on metabolism-related
diseases and cardiovascular pathologies. It will co-develop some products with academic teams and will set up strategic alliances and commercial partnerships to cover all areas of research in life sciences.
The company is headquartered in Jersey City, New Jersey, USA. It has a
European office in France under the leadership of Lionel Ségard.
For more information go to www.Quantum-Genomics.com